JP2025500784A - 結腸直腸癌を治療するためのアミバンタマブの使用 - Google Patents

結腸直腸癌を治療するためのアミバンタマブの使用 Download PDF

Info

Publication number
JP2025500784A
JP2025500784A JP2024534144A JP2024534144A JP2025500784A JP 2025500784 A JP2025500784 A JP 2025500784A JP 2024534144 A JP2024534144 A JP 2024534144A JP 2024534144 A JP2024534144 A JP 2024534144A JP 2025500784 A JP2025500784 A JP 2025500784A
Authority
JP
Japan
Prior art keywords
antibody
seq
subject
administered
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500784A5 (cg-RX-API-DMAC7.html
Inventor
ノブラウチ,ローランド
Original Assignee
ヤンセン バイオテツク,インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク,インコーポレーテツド filed Critical ヤンセン バイオテツク,インコーポレーテツド
Publication of JP2025500784A publication Critical patent/JP2025500784A/ja
Publication of JP2025500784A5 publication Critical patent/JP2025500784A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024534144A 2021-12-09 2022-12-09 結腸直腸癌を治療するためのアミバンタマブの使用 Pending JP2025500784A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163287557P 2021-12-09 2021-12-09
US63/287,557 2021-12-09
US202163290765P 2021-12-17 2021-12-17
US63/290,765 2021-12-17
PCT/IB2022/061991 WO2023105479A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer

Publications (2)

Publication Number Publication Date
JP2025500784A true JP2025500784A (ja) 2025-01-15
JP2025500784A5 JP2025500784A5 (cg-RX-API-DMAC7.html) 2025-12-12

Family

ID=84537874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534144A Pending JP2025500784A (ja) 2021-12-09 2022-12-09 結腸直腸癌を治療するためのアミバンタマブの使用

Country Status (9)

Country Link
US (2) US20230183360A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444426A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500784A (cg-RX-API-DMAC7.html)
KR (1) KR20240112963A (cg-RX-API-DMAC7.html)
AU (1) AU2022407875A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241933A1 (cg-RX-API-DMAC7.html)
IL (1) IL313410A (cg-RX-API-DMAC7.html)
MX (1) MX2024007066A (cg-RX-API-DMAC7.html)
WO (1) WO2023105479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202547867A (zh) * 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
WO2026022733A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026150367A1 (en) * 2025-01-13 2026-07-16 Janssen Biotech, Inc. Bispecific anti-egfr/c-met antibody-drug conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
BR112022015140A2 (pt) * 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met

Also Published As

Publication number Publication date
KR20240112963A (ko) 2024-07-19
AU2022407875A1 (en) 2024-07-25
CA3241933A1 (en) 2023-06-15
EP4444426A1 (en) 2024-10-16
MX2024007066A (es) 2024-06-21
US20250257139A1 (en) 2025-08-14
IL313410A (en) 2024-08-01
WO2023105479A1 (en) 2023-06-15
US20230183360A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP7703448B2 (ja) 二重特異性抗egfr/c-met抗体による併用療法及び患者層別化
ES3041987T3 (en) Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
US20250257139A1 (en) Use of Amivantamab to Treat Colorectal Cancer
JP7783182B2 (ja) c-METエクソン14スキッピング変異を有する患者の治療
JP2023539589A (ja) Egfr変異を有する非小細胞肺がんの治療
KR20260013482A (ko) 비-소세포 폐암(nsclc)의 치료 방법
JP2025505642A (ja) Egfr/met二重特異性抗体で処置された患者における注入関連反応を低減するための方法
US20220372581A1 (en) Methods for Identifying Cancer Patients for Combination Treatment
WO2025153988A1 (en) Use of amivantamab to treat colorectal cancer
KR20260066109A (ko) 비소세포 폐암을 치료하는 방법
KR20250158056A (ko) 이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
US20220298248A1 (en) Treatment of Cancers Lacking EGFR- Activating Mutations
US20260048065A1 (en) Methods for treatment of non-small cell lung cancer (nsclc)
WO2026038160A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
HK40116078A (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
CN118414167A (zh) 埃万妥单抗用于治疗结肠直肠癌的用途
HK40108897A (en) Use of amivantamab to treat colorectal cancer
HK40104478A (en) Methods for identifying cancer patients for combination treatment
CA3222287A1 (en) First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
CN118679186A (zh) 用于减少使用egfr/met双特异性抗体治疗的患者的输注相关反应的方法
EA050376B1 (ru) ЛЕЧЕНИЕ ПАЦИЕНТОВ, ИМЕЮЩИХ МУТАЦИИ, ВЫЗЫВАЮЩИЕ ПРОПУСК ЭКЗОНА 14 В c-Met

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251204